RE:WELL Target PricesIn 2021 the median analyst price target for WELL was $12. The low target was $10 and high was $20. If we want to be more optimistic, speedy's price target was low $25 and high $50, as he said it was inevitable. These analyst were all wrong and forced to revise their price target every other month. Unless you are a complete moron or a boiler room pumper that swindles investors (@CBDT) then surely even the most optimistic of investors couldn't possibly believe these analysts are all right. There you go smokey, you got any more advice on CBDT, the investors there are still waiting for your advice, since CBDT is under cease trade order and being delisted....
One thing I will give to WELL managment is how well they utilize all their paid analyst and brokers and NRs to take advantage of the markets daily movement. They see dow rally, they hastily puts out rosy NRs and get all their paid advertisers to promote. These NR's really has no substance if you look past the headlines. Now they will add Grand Canyon Anasthesia full revenue to WELL's financials when the next one comes out and calls it another record quarterly's in revenue. Lolololol... Did people even dissect the article properly instead of just reading the headlines. Like I said watch next week when the insiders trading report comes out, I bet these guys are selling. This is just how it is. Cheers. That is the lesson for today.
From a profitability standpoint, both businesses contributed positive adjusted EBITDA in the quarter, although we expect that the contribution was minimal.
Shareholder EBITDA margins of 12.5% equate to ~18% operating EBITDA margins if we assume a typical operating profile, where shareholder EBITDA is 70% of operating EBITDA. That margin profile is notably worse than CRH’s typical EBITDA margins.